Illumina unveils new gene sequencing device with bargain price tag

Illumina is rolling out its latest gene sequencing machine, the iSeq 100, priced at just under $20,000.

Illumina, the maker of DNA sequencers, unveiled its latest device. With a price tag of just under $20,000, the company hopes it will open the doors for more researchers to study viruses, bacteria and other microbes.

The company’s new iSeq 100 sequencing device, which measures about 1 cubic foot, is priced at $19,900. It combines Illumina’s sequencing by synthesis chemistry with metal-oxide-semiconductor detection technology.

The device, which Illumina touts as being the most powerful of its type for its size, is part of an effort to position next-generation gene sequencing as a standard for discovery research and routine genomic testing for a wide range of customers, markets and applications.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Now “any researcher can have access to the accuracy of an Illumina sequencer in their lab,” Francis deSouza, Illumina’s president and CEO, said in a statement. “The iSeq 100 offers robustness and reliability for a broad range of applications ranging from germline and somatic tumor profiling to 16S microbial analysis and targeted gene expression.”

The device is expected to begin shipping in the first quarter, the company said, adding that it is working to increase the device’s output and reduce its run time in an effort to expand the iSeq 100 into other markets like rapid microbiome sequencing, testing for foodborne pathogens and monitoring hospital acquired infections.

Read more on

Suggested Articles

Biotronik received FDA approvals for six high-voltage cardiac rhythm management devices for treating and resynchronizing tachycardia and arrhythmias.

IRhythm’s ECG patch was able to improve atrial fibrillation diagnoses and lower numbers of ER visits by shifting patients to outpatient settings.

Novartis’ Alcon unit is picking up 2016 Fierce 15 company PowerVision in a $285 million deal for its flexible, fluid-based intraocular lens.